PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today the company has received a Bronze Edison Award for the company’s UroLift® System, a novel minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), also called enlarged prostate. Awards were presented during a gala event last night at Capitale in New York City.
“The Edison Awards not only honor innovative ideas, but also take a close look at the value and impact of new technologies and products,” said Dave Amerson, CEO of NeoTract. “With a much-needed minimally invasive treatment alternative for BPH, the UroLift System is truly making a difference in these areas, and the recognition is gratifying. We are just as pleased that the physician community is embracing the UroLift System, giving men with BPH a better quality of life.”
Unlike traditional BPH surgery and most prostate medications, the FDA-cleared UroLift System is clinically proven to preserve sexual function. Delivered during a minimally invasive outpatient procedure, often under local anesthesia, the tiny UroLift implants relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Patients experience immediate results, rapid symptom relief, recover from the procedure quickly, and return to their normal routines with minimal downtime.
Ted Lamson, PhD, NeoTract co-founder accepted the award: “On behalf of my co-inventors and then entire NeoTract organization, we are honored and pleased to receive this prestigious award. While the most rewarding aspect of having conceived of the UroLift system treatment is knowing that thousands and soon, millions – of men will experience relief from prostate issues without the risks of traditional surgery, it is also incredibly gratifying to know that my peers in the field of product design also value this innovative solution.”
The ballot of nominees for the Edison Award are judged on their excellence in concept, value, delivery and impact. Participating innovators fall into one of sixteen categories. The members of the Edison Awards Steering Committee are senior executives with diverse marketing, scientific, and business backgrounds who monitor the development and successful launch of innovative products each year.
The Edison Awards, named after Thomas Alva Edison, has honored some of the most creative and innovative leaders in the world. For more information about the Edison Awards and a list of past winners please visit www.edisonawards.com.
About Benign Prostatic Hyperplasia (BPH)
BPH, also known as enlarged prostate, is a medical condition in which the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. The condition is common, affecting approximately 37 million men in the United States alone. BPH symptoms include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life. About one in four men experience BPH-related symptoms by age 55 and by age 70, over 80 percent of men suffer from BPH.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra. While current surgical options, such as transurethral resection of the prostate (TURP), can be very effective in relieving symptoms, it can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
MAC00215-01 Rev A